Search research articles
Contact Us
Filters
Showing results (41-50 of 86) with videos related to
Page
of 9
Sort By:
Cancer
|
September 29, 2024
Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma
Christopher D Lao, James Moon, Vincent T Ma, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial
Dirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer
|
July 29, 2018
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
Joseph I Clark, Jatinder Singh, Marc S Ernstoff, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
April 5, 2013
Clinicopathologic features of primary Merkel cell carcinoma: a detailed descriptive analysis of a large contemporary cohort
Jennifer L Schwartz, Christopher K Bichakjian, Lori Lowe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
Shailender Bhatia, Suzanne L Topalian, William Sharfman, et al.
BMC Cancer
|
April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
BMC Cancer
|
May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Translational Oncology
|
April 17, 2016
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial
Michelle M Kim, Hemant Parmar, Yue Cao, et al.
Journal for Immunotherapy of Cancer
|
September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 86) with videos related to
Sort By:
Page
of 9
Cancer
|
September 29, 2024
Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma
Christopher D Lao, James Moon, Vincent T Ma, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial
Dirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer
|
July 29, 2018
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
Joseph I Clark, Jatinder Singh, Marc S Ernstoff, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
April 5, 2013
Clinicopathologic features of primary Merkel cell carcinoma: a detailed descriptive analysis of a large contemporary cohort
Jennifer L Schwartz, Christopher K Bichakjian, Lori Lowe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
Shailender Bhatia, Suzanne L Topalian, William Sharfman, et al.
BMC Cancer
|
April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
BMC Cancer
|
May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Translational Oncology
|
April 17, 2016
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial
Michelle M Kim, Hemant Parmar, Yue Cao, et al.
Journal for Immunotherapy of Cancer
|
September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Page
of 9